Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy

Inclusion Criteria: * Confirmed acute index (original venous thrombotic) event: lower extremity or upper extremity (jugular, innominate, subclavian, axillary, brachial) DVT, PE, splanchnic (hepatic, portal, splenic, mesenteric, renal, gonadal), or cerebral vein thrombosis for which the patient has received \>= 180 days (but =\< 365 days) of anticoagulant therapy prior to registration; the date, imaging modality, and location of index event will be required; the date of initiation and specific type of anticoagulants used will also be required * Active cancer defined as metastatic disease and/or any evidence of cancer on cross-sectional or positron emission tomography (PET) imaging, cancer related surgery, chemotherapy or radiation therapy within the past 6 months; Note: non-melanoma skin cancer does not meet the cancer requirement * Life expectancy \>= 6 months * Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2 * Hemoglobin \>= 8 g/dL obtained =\< 30 days prior to registration * Platelet count \>= 50,000/mm\^3 obtained =\< 30 days prior to registration * Alanine aminotransferase (ALT) or aspartate transaminase (AST) =\< 3 x upper limit of normal (ULN) obtained =\< 30 days prior to registration * Calculated creatinine clearance must be \>= 30 ml/min using the Cockcroft-Gault formula obtained =\< 30 days prior to registration * Negative serum or urine pregnancy test done =\< 7 days prior to registration, for women of childbearing potential only; …